Wider Than AZ’s PACIFIC – Novartis Has Broad NSCLC Plans For Canakinumab
Novartis is taking its unexpected CANTOS cancer findings for canakinumab and running with them to Phase III in an adjuvant lung cancer setting that is broader that AstraZeneca's PACIFIC study.
You may also be interested in...
After deciding to examine canakinumab's potential in lung cancer on the back of the CANTOS cardiovascular trial, Novartis designed a major late-stage program in oncology for the interleukin-1 beta inhibitor. The second of those CANOPY trials has just come crashing down.
The Swiss firm's canakinumab has proved to be an effective treatment for several inflammation-driven rare conditions but disappointment from the CANOPY-2 trial suggests that cancer will follow cardiovascular as an indication where the therapy falls by the wayside.
Novartis immunology chief Eric Hughes tells Scrip a wealth of data is showing that early treatment with Cosentyx can prevent the structural changes that lead to lack of mobility in ankylosing spondylitis and psoriatic arthritis patients.